Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 298, Issue 3, 2010, Pages

  Shang, Quan ^a   Saumoy, Monica ^b   Holst, Jens Juul ^c   Salen, Gerald ^a   Xu, Guorong ^a,b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cholesterol 7 hydroxylase; Fatty acid; Glucagon like peptide 1; Intestinal absorption

Indexed keywords

BILE ACID; COLESEVELAM; FARNESOID X RECEPTOR; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIET; FEEDING; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID DIET; MALE; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PORTAL VEIN BLOOD; PRIORITY JOURNAL; PROTEIN SECRETION; RAT;

ALLYLAMINE; ANIMALS; ANTICHOLESTEREMIC AGENTS; BILE ACIDS AND SALTS; BLOOD GLUCOSE; BODY WEIGHT; CARRIER PROTEINS; CHOLESTEROL; CHOLESTEROL 7-ALPHA-HYDROXYLASE; CYCLIC N-OXIDES; DIETARY CARBOHYDRATES; DIETARY FATS; GENE EXPRESSION; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; ILEUM; INSULIN; INSULIN RESISTANCE; LIVER; MALE; MEMBRANE GLYCOPROTEINS; OBESITY; ORGANIC ANION TRANSPORTERS, SODIUM-DEPENDENT; PORTAL VEIN; RATS; RATS, INBRED F344; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SYMPORTERS; TRIGLYCERIDES; TROPANES;

EID: 77249142314     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00362.2009     Document Type: Article

References (24)

1. Bays HE, Goldberg RB. The "forgotten" bile acid sequestrants: is now a good time to remember? Am J Ther 14: 567-580, 2007.
2. Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med 168: 1975-1983, 2008.
3. Cariou B, van Harmelen K, Duran-Sandoval D, van Dijk TH, Grefhorst A, Abdelkarim M, Caron S, Torpier G, Fruchart JC, Gonzalez GJ, Kuipers F, Staels B. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem 281: 11039-11049, 2006.
4. De Fabiani E, Mitro N, Gilardi F, Caruso D, Galli G, Crestani M. Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle. J Biol Chem 278: 39124-39132, 2003.
5. Dumoulin V, Moro F, Barcelo A, Dakka T, Cuber JC. Peptide YY, glucagon-like peptide-1, and neurotensin responses to luminal factors in the isolated vascularly perfused rat ileum. Endocrinology 139: 3780-3786, 1998.
6. Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V. Glucagon-like peptide-1(7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute postprandial and 24-h secretion patterns. J Endocrinol 138: 159-166, 1993.
7. Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 31: 1479-1484, 2008.
8. Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med 168: 1531-1540, 2008.
9. Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M, Sugimoto Y, Miyazaki S, Tsujimoto G. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med 11: 90-94, 2005.
10. Holst JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev 18: 430-441, 2002.
11. Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun 329: 386-390, 2005.
12. Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M, Fukusumi S, Habata Y, Itoh T, Shintani Y, Hinuma S, Fujisawa Y, Fujino M. A G protein-coupled receptor responsive to bile acids. J Biol Chem 278: 9435-9440, 2003.
13. Knoebel LK. Intestinal absorption in vivo of micellar and nonmicellar lipid. Am J Physiol 223: 255-261, 1972.
14. Lauffer LM, Iakoubov R, Brubaker PL. GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes 58: 1058-1066, 2009.
15. Levin BE, Dunn-Meynell AA, McMinn JE, Alperovich M, Cunningham-Bussel A, Chua SC Jr. A new obesity-prone, glucose-intolerant rat strain (F. DIO). Am J Physiol Regul Integr Comp Physiol 285: R1184-R1191, 2003.
16. Li H, Xu G, Shang Q, Pan L, Shefer S, Batta AK, Bollineni J, Tint GS, Keller BT, Salen G. Inhibition of ileal bile acid transport lowers plasma cholesterol levels by inactivating hepatic FXR and stimulating CYP7A1. Metabolism 53: 927-932, 2004.
17. Ma K, Saha PK, Chan L, Moore DD. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 116: 1102-1109, 2006.
18. Rocca AS, Brubaker PL. Stereospecific effects of fatty acids on proglucagon-derived peptide secretion in fetal rat intestinal cultures. Endocrinology 136: 5593-5599, 1995.
19. Rocca AS, Lagreca J, Kalitsky J, Brubaker PL. Monounsaturated fatty acid diets improve glycemic tolerance through increased secretion of glucagon-like peptide-1. Endocrinology 142: 1148-1155, 2001.
20. Staels B, Kuipers F. Bile acid sequestrants and the treatment of type 2 diabetes mellitus. Drugs 67: 1383-1392, 2007.
21. Suzuki T, Oba K, Igari Y, Matsumura N, Watanabe K, Futami-Suda S, Yasuoka H, Ouchi M, Suzuki K, Kigawa Y, Nakano H. Colestimide lowers plasma glucose levels and increase plasma glucagon-like peptide-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia. J Nippon Med Sch 74: 338-343, 2007.
22. Yamagata K, Daitoku H, Shimamoto Y, Matsuzaki H, Hirota K, Ishida J, Fukamizu A. Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. J Biol Chem 279: 23158-23165, 2004.
23. Yoder SM, Yang Q, Kindel TL, Tso P. Stimulation of incretin secretion by dietary lipid: is it dose dependent? Am J Physiol Gastrointest Liver Physiol 297: G299-G305, 2009.
24. Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, Willson TM, Edwards PA. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA 103: 1006-1011, 2006.